Journal
IMMUNITY
Volume 44, Issue 4, Pages 722-724Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2016.03.014
Keywords
-
Categories
Ask authors/readers for more resources
Although it is successful for some, most melanoma patients are refractory to T cell checkpoint inhibition. In this issue of Immunity, Merad and colleagues (2016) describe a dendritic-cell-based strategy to heighten the efficacy of therapeutic anti-PD-L1 and BRAF inhibitors in mouse melanoma models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available